Nexgard is a drug owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC. It is protected by 14 US drug patents filed from 2026 to 2033. All patents are active. Details of Nexgard’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US9931320 | 31 Jan, 2033 | Active |
| US9931320 | 31 Jan, 2033 | Active |
| US8410153 | 20 Jun, 2028 | Active |
| US8410153 | 20 Jun, 2028 | Active |
| US7964204 | 25 Jan, 2028 | Active |
| US7964204 | 25 Jan, 2028 | Active |
| US8623875 | 28 Dec, 2026 | Active |
| US8623875 | 28 Dec, 2026 | Active |
| US8231888 | 28 Dec, 2026 | Active |
| US8231888 | 28 Dec, 2026 | Active |
| US9095138 | 28 Dec, 2026 | Active |
| US9095138 | 28 Dec, 2026 | Active |
Exclusivity Information
Nexgard holds 2 exclusivitys out of which 2 have expired. Details of Nexgard's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Sep 14, 2018 |
| NCI | Apr 01, 2017 |
Nexgard Petitions
Details of Nexgard's suitability petitions are listed below.
| Petitioner | Action | Date of Action | Description |
|---|---|---|---|
 | |||
| Aurora Pharmaceutical, Inc. | Approved | 02 May, 2024 | The proposed change is for an oral solution ; the RLNAD is approved as soft chewables in 11.3 mg, 28.3 mg, 68 mg, and 136 mg strengths. |
About Nexgard
Nexgard is a drug
owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC.
Nexgard uses
Afoxolaner as the active
ingredient.
Active Ingredient:
Nexgard uses
Afoxolaner as the active ingredient.
Check out other Drugs and Companies using
Afoxolaner ingredient.